- Home
- EVAX vs KRKR Comparison
EVAX vs KRKR Comparison
Compare EVAX & KRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- KRKR
- Stock Information
- Founded
- EVAX 2008
- KRKR 2010
- Country
- EVAX Denmark
- KRKR China
- Employees
- EVAX N/A
- KRKR N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- KRKR Business Services
- Sector
- EVAX Health Care
- KRKR Consumer Discretionary
- Exchange
- EVAX Nasdaq
- KRKR Nasdaq
- Market Cap
- EVAX 8.7M
- KRKR 6.6M
- IPO Year
- EVAX 2021
- KRKR 2019
- Fundamental
- Price
- EVAX $2.62
- KRKR $5.99
- Analyst Decision
- EVAX Strong Buy
- KRKR
- Analyst Count
- EVAX 3
- KRKR 0
- Target Price
- EVAX $33.33
- KRKR N/A
- AVG Volume (30 Days)
- EVAX 6.9M
- KRKR 1.3M
- Earning Date
- EVAX 03-26-2025
- KRKR 09-03-2024
- Dividend Yield
- EVAX N/A
- KRKR N/A
- EPS Growth
- EVAX N/A
- KRKR N/A
- EPS
- EVAX N/A
- KRKR N/A
- Revenue
- EVAX $3,295,000.00
- KRKR $41,654,350.00
- Revenue This Year
- EVAX $4,845.21
- KRKR $45.99
- Revenue Next Year
- EVAX $30.30
- KRKR $31.46
- P/E Ratio
- EVAX N/A
- KRKR N/A
- Revenue Growth
- EVAX N/A
- KRKR N/A
- 52 Week Low
- EVAX $2.22
- KRKR $2.76
- 52 Week High
- EVAX $23.70
- KRKR $12.99
- Technical
- Relative Strength Index (RSI)
- EVAX 41.09
- KRKR 59.72
- Support Level
- EVAX $2.22
- KRKR $4.99
- Resistance Level
- EVAX $4.05
- KRKR $7.00
- Average True Range (ATR)
- EVAX 1.17
- KRKR 1.48
- MACD
- EVAX 0.00
- KRKR 0.17
- Stochastic Oscillator
- EVAX 6.99
- KRKR 30.19
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.